The EMA evaluates cancer medicines through its Committee for Medicinal Products for Human Use (CHMP). This committee conducts a rigorous assessment of the drug's clinical trial data, focusing on its efficacy, safety, and quality. The evaluation process includes preclinical studies, clinical trials (phases I-III), and post-marketing surveillance.
